Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Previously Treated Metastatic Pancreatic Adenocarcinoma
NCT05014776Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Aug 2022
- Primary completion
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors, Small Molecules, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of CRS-207, pembrolizumab, ipilimumab, tadalafil in pancreatic adenocarcinoma (PDAC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Aug 2022; status: completed.
02
Drugs
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05014776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05014776.